Nearly 4 in 10 people with pulmonary sarcoidosis had a relapse after reducing or stopping treatment, according to a…
Articles by Andrea Lobo, PhD
Levels of specific immune complement proteins in blood and cerebrospinal fluid, including C3, factor B, and C5, showed strong potential…
Atyr Pharma plans to launch a new global clinical trial to test its investigational therapy, efzofitimod, in people with pulmonary…
Corticosteroid treatment leads to rapid improvements in kidney function in people with renal sarcoidosis, but later relapses are frequent,…
Black/African American people with sarcoidosis are more likely than non-Hispanic white patients to develop certain eye problems, including inflammation…
People with autoimmune diseases — especially Sjögren’s disease, which affects the glands that produce tears and saliva — may…
The global burden of pulmonary sarcoidosis and other interstitial lung diseases (ILDs) increased significantly between 1990 and 2023, with…
A new artificial intelligence (AI) model predicted sudden cardiac death (SCD) risk more accurately than current clinical guidelines in people…
A mobile health app designed to guide breathing awareness meditation (BAM) sessions may effectively reduce fatigue and stress and…
Among second-line treatments for sarcoidosis, methotrexate is safer and associated with a lower risk of hospitalization, intensive care,…